Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

iShares 0 3 Month Treasury Bond ETFTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

iShares 0 3 Month Treasury Bond ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.51, while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

SGOVVRTX
Sector
Fixed IncomeHealth
52-Week High
$100.74$529.65
52-Week Low
$100.28$376.62
Market Cap
$134.25B
Enterprise Value
$128.37B

Returns comparison

Trailing returns across standard periods

About iShares 0 3 Month Treasury Bond ETF

SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.

Read more on SGOV

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX